Kellogg Joshua J, Alonso Maria Natalia, Jordan R Teal, Xiao Junpei, Cafiero Juan Hilario, Bush Trevor, Chen Xiaoling, Towler Melissa, Weathers Pamela, Shell Scarlet S
Department of Veterinary & Biomedical Sciences, Pennsylvania State University, University Park, PA, 16802, USA.
Department of Biology & Biotechnology, Worcester Polytechnic Institute, Worcester, MA 01609, USA.
J Ethnopharmacol. 2024 Oct 28;333:118500. doi: 10.1016/j.jep.2024.118500. Epub 2024 Jun 27.
African wormwood (Artemisia afra Jacq. ex Willd.) has been used traditionally in southern Africa to treat illnesses causing fever and was recently shown to possess anti-tuberculosis activity. As tuberculosis is an endemic cause of fever in southern Africa, this suggests that the anti-tubercular activity of A. afra may have contributed to its traditional medicinal use.
Tuberculosis, caused by Mycobacterium tuberculosis (Mtb), is a deadly and debilitating disease globally affecting millions annually. Emerging drug-resistant Mtb strains endanger the efficacy of the current therapies employed to treat tuberculosis; therefore, there is an urgent need to develop novel drugs to combat this disease. Given the reported activity of A. afra against Mtb, we sought to determine the mechanisms by which A. afra inhibits and kills this bacterium.
We used transcriptomics to investigate the impact of Artemisia spp. extracts on Mtb physiology. We then used chromatographic fractionation and biochemometric analyses to identify a bioactive fractions of A. afra extracts and identify an active compound.
Transcriptomic analysis revealed that A. afra exerts different effects on Mtb compared to A. annua or artemisinin, suggesting that A. afra possesses other phytochemicals with unique modes of action. A biochemometric study of A. afra resulted in the isolation of an O-methylflavone (1), 5-hydroxy-7-methoxy-2-(4-methoxyphenyl)chromen-4-one, which displayed considerable activity against Mtb strain mc6230 in both log phase growth and metabolically downshifted hypoxic cultures.
The present study demonstrated that an O-methylflavone constituent of Artemisia afra explains part of the activity of this plant against Mtb. This result contributes to a mechanistic understanding of the reported anti-tubercular activity of A. afra and highlights the need for further study of this traditional medicinal plant and its active compounds.
非洲苦艾(Artemisia afra Jacq. ex Willd.)在南部非洲传统上被用于治疗引起发热的疾病,最近被证明具有抗结核活性。由于结核病是南部非洲发热的地方性病因,这表明非洲苦艾的抗结核活性可能促成了其传统药用。
由结核分枝杆菌(Mtb)引起的结核病是一种致命且使人衰弱的疾病,全球每年有数百万人受其影响。新出现的耐药结核分枝杆菌菌株危及当前用于治疗结核病的疗法的疗效;因此,迫切需要开发新型药物来对抗这种疾病。鉴于已报道非洲苦艾对结核分枝杆菌有活性,我们试图确定非洲苦艾抑制和杀死这种细菌的机制。
我们使用转录组学来研究蒿属植物提取物对结核分枝杆菌生理学的影响。然后我们使用色谱分离和生物计量分析来鉴定非洲苦艾提取物的生物活性部分并鉴定一种活性化合物。
转录组分析表明,与青蒿或青蒿素相比,非洲苦艾对结核分枝杆菌有不同的作用,这表明非洲苦艾含有其他具有独特作用方式的植物化学物质。对非洲苦艾的生物计量研究导致分离出一种O - 甲基黄酮(1),即5 - 羟基 - 7 - 甲氧基 - 2 -(4 - 甲氧基苯基)色原酮 - 4 - 酮,它在对数期生长和代谢下调的低氧培养物中对结核分枝杆菌菌株mc6230均表现出相当大的活性。
本研究表明,非洲苦艾中的一种O - 甲基黄酮成分解释了该植物对结核分枝杆菌活性的部分原因。这一结果有助于从机制上理解已报道的非洲苦艾的抗结核活性,并强调需要对这种传统药用植物及其活性化合物进行进一步研究。